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Purpose: The aim of this work was to study the inﬂuence of solidiﬁcation of meloxicam
(Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability
of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer,
but no surfactant as a further stabilizing agent because the ﬁnal aim was to produce
surfactant-free solid phase products as well.
Methods: The solidiﬁed samples produced by ﬂuidization and lyophilization (ﬂuidMel,
lyoMel) were examined for particle size, crystallinity, and in vitro release of Mel compared
to similar parameters of nanoMel. The products were subjected to an animal experiment
using per oral administration to verify their bioavailability.
Results: Mel containing (1%) nanoMel sample was produced by wet milling process using
an optimized amount of PVA (0.5%) which resulted in 130 nm as mean particle size and
a signiﬁcant reduction in the degree of crystallinity (13.43%) of Mel. The ﬂuidization
technique using microcrystalline cellulose (MCC) as carrier resulted in a quick conversion
and no signiﬁcant change in the critical product parameters. The process of lyophilization
required a longer operation time, which resulted in the amorphization of the crystalline
carrier (trehalose) and the recrystallization of Mel increased its particle size and crystallinity.
The ﬂuidMel and lyoMel samples had nearly ﬁve-fold higher relative bioavailability than
nanoMel application by oral administration. The correlation between in vitro and in vivo
studies showed that the ﬁxed Mel nanoparticles on the surface of solid carriers (MCC,
trehalose) in both the artiﬁcial gastric juice and the stomach of the animals rapidly reached
saturation concentration leading to faster dissolution and rapid absorption.
Conclusion: The solidiﬁcation of the nanosuspension not only increased the stability of the
Mel nanoparticles but also allowed the preparation of surfactant-free compositions with
excellent bioavailability which may be an important consideration for certain groups of
patients to achieve rapid analgesia.
Keywords: solidiﬁcation, ﬂuidization, lyophilization, surfactant-free product, rapid drug
absorption, IVIV correlation
Introduction
Nanosuspensions can be deﬁned as colloidal dispersions of nanosized drug particles
(<500 nm) that are produced by different nanonization processes and stabilized by
various excipients.1 Nanonization of drugs with different top-down methods (wet-
bead milling, high-pressure homogenization and microﬂuidization) is a proven
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effective strategy to decrease the particle size by mechan-
ical processes and to enhance the dissolution rate, satura-
tion solubility and bioavailability of poorly water-soluble
active ingredients, such as BCS class II (poorly soluble
and high permeable) and Class IV (poorly soluble and
permeable).2,3 Nanosuspensions produced by milling are
generally unstable; therefore, stabilizing agents (polymers,
surfactants) and its transformation to the solid-state have
an important role in the formulations with long-term
stability.4,5 Water-soluble polymers, such as 2.4−19.6%
of cellulose ethers,6 30% of poly(vinyl pyrrolidone),7,8
and 50% of poly(vinyl alcohol),9,10 are mainly used in
wet milling. The most commonly used surfactants and
their amount in relation to the amount of active ingredient
are as follows: CremophorR (100%),11 Poloxamer 188
(60%),12 Poloxamine 908 (20%),13 Tyloxapol (20%),14
sodium lauryl sulfate (0.15%),15 and Polysorbate 80
(1%).16,17 In the absence of stabilizers, the high surface
energy of nanosized drug particles can induce aggregation/
agglomeration in the system.18 The main functions of
stabilizers in nanosuspensions are to wet drug particles
during the milling process and to prevent Ostwald’s ripen-
ing (crystal growth in colloidal suspensions)19 and
agglomeration in order to yield a physically stable formu-
lation by providing steric or ionic barriers. Different con-
centrations of stabilizer agents (eg, polymers) can also
inﬂuence the viscosity and the electro-kinetic property of
the particles, according to the DLVO theory,20 and thus the
stability of the nanosuspension as well. Surfactants help to
wet the particles and thus reduce their aggregation ten-
dency. In addition to the advantages of surfactants, they
have the biggest disadvantage of increasing the speed/
energy of motion of the milling balls during wet milling,
which can lead to the degradation of the active ingredient.
When used as an external surfactant to solidify the nano-
suspension, its solubility-enhancing effect may be empha-
sized, thereby increasing the degree of crystallinity of
active agent in the solid product and reducing its dissolu-
tion rate.21 Conventional formulations contain these exci-
pients in common, but the new tendency is to ignore the
surfactants and look for other options to stabilize the
nanoparticles in the products and achieve the desired bio-
logical effect.22–24
Crystalline state is one of the most important para-
meters affecting drug stability, dissolution extent, and efﬁ-
cacy. The high energy wet milling techniques tend to
create a partially amorphous active agent. The high energy
amorphous particles are unstable, especially in the
presence of crystalline particles, and inclined to convert
to low energy crystalline state over time. The saturation
solubility between amorphous and crystalline nanoparti-
cles is different; therefore, the diffusion process will be
similar to Oswald’s ripening, leading to a rapid conversion
of amorphous nanoparticles to crystalline state.25
Of course, the nanosuspensions can be applied as ﬁnal
liquid dosage forms using further different excipients
(viscosity enhancer, ﬂavoring, preservative agents, etc.);
however, their stabilization is a major challenge.26 It is
well known that, despite the stabilization, nanosuspensions
have a short expiration time, and there are patients who do
not prefer this form or the presence of a surfactant. One
way to overcome the instability and surfactant problem is
to design solid nanosuspension produced by spray drying,
spray freeze drying and freeze drying (lyophilization). It is
well known that dry nanosuspensions can cause difﬁculty
in hydration and redispersibility.24,27 Other processes for
transforming a nanosuspension into solid-state forms
(tablets, capsules) are very different: deposition as coat-
ings, incorporation in granules and pellets and the 3D
printing technologies.28
Spray drying and lyophilization (freeze drying) are the
commonly used techniques for the solidiﬁcation of nano-
suspension because of their easy application and industrial
acceptability.29 The powders produced by these processes
often suffer from poor ﬂowability and high hygroscopi-
city; therefore, other technologies are applied to transform
nanosuspensions into oral dosage forms as tablets and
capsules.30
Layering of nanosuspension onto the surface of gran-
ules, pellets, sugar beads, etc., using a ﬂuidization techni-
que is used as an alternative method for solidiﬁcation of
nanosuspension.30–32 The advantages of this process that
may use various additives in order to achieve the desired
purpose are as follows: (i) different polymers stabilize the
nanosuspension and act as coating materials resulted in
fast dissolution rate; (ii) surfactants prevent the aggrega-
tion of nanoparticle and can modify the drug release.15 In
any case, the ﬂuidization technique also provides an
opportunity to stabilize the broken structure of the ground
crystals in the nanosuspension by using crystallization
inhibitors.33
Mel, a member of the oxicam family of NSAIDs (non-
steroidal anti-inﬂammatory drugs), as a moderately selec-
tive cyclooxygenase (COX-2) inhibitor can have a role in
acute pain therapy, but a basic requirement is a rapid
absorption through the gastric mucosa. Mel has a weak
Bartos et al Dovepress
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acidic character with pKa of 3.43; therefore, its solubility
in gastric juice (pH=1.2) is very poor but its logPapp is
2.43 (pH=2.0), which predestines the fast absorption from
the stomach.34–36 Since the solubility of Mel is very poor
in gastric juice, the preparation of a nanosuspension with
a fast dissolution rate may be a solution.
In our previous work, we developed a wet milling
procedure for the nanonization of Mel, which was reported
in the DDDT in 2018.10 We optimized the critical process
parameters by factorial design (ratio of predispersion and
pearls, milling time and rotation speed of the steel jar) and
investigated the PVA amount on the particle size distribu-
tion and crystallinity of the Mel. The optimized process
parameters and PVA amount have allowed the use of no
surfactant during milling to prevent aggregation. We had
also the surfactant-free nanosuspension as intermediate
product showed a stable system for critical product para-
meters with 2 weeks of holding time.
The main purpose of the work was to produce
a surfactant-free product by solidifying of Mel-containing
nanosuspension. Critical product parameters were consid-
ered to be the particle size distribution of the drug (d(0.9)
<500 nm), stabilization of the degree of crystallinity altered
during milling, and enhancement of the bioavailability of the
solid product with fast absorption from the stomach for rapid
analgesia. The transformation of the nanosuspension was
done by ﬂuidization and lyophilization.
Materials and Methods
Materials
Mel (rawMel) was obtained from EGIS Ltd. (Budapest,
Hungary). PVA-MowiolR 4–98 (Mw ~27,000) (Sigma
Aldrich Co. LLC, St. Louis MO, USA) was used as
a stabilizing agent. Zirconium oxide (ZrO2) beds with
a diameter of 0.30 mm were obtained from Netsch (Netsch
GmbH, Selb, Germany). Microcrystalline cellulose (MCC)
(AvicelR PH 101, FMC Biopolymer, Philadelphia USA) was
used as a carrier material for the ﬂuidized product. D-(+)-
trehalose dihydrate as a cake-forming agent was purchased
from Karl Roth GmbH + Co. KG. (Karlsruhe, Germany).
Methods
Preparation of Nanosuspension (nanoMel)
For the production of the Mel nanosuspension, a planetary
ball mill was combined with pearl milling technology. PVA
was used as a stabilizing additive, 1.0 g of PVAwas dissolved
in 17.0 g of distilled water as a dispersant medium, in which
2.0 g of Mel was suspended. The milling was executed using
a Retsch PM 100 planetary ball mill (Retsch GmbH, Haan,
Germany) at 437 rpm rotation speed for 43 min in addition
with 20.0 g of 0.3 mm ZrO2 beads as a milling medium.
After the milling process, to eliminate the grinding medium
from the sample, a 0.150-mm sieve was used. The nanosus-
pension was removed from the beads by cleaning with dis-
tilled water, while the milled sample was ten-fold diluted.
The yield of the milling process was 94.93%. The ﬁnal
concentration of the components can be seen in Table 1.
Transformation of Nanosuspension into Solid-State
Form
In the preformulation study, surfactant-free and external sur-
factant-containing (Polysorbate 80) samples were produced
by ﬂuidization to study the critical parameters of the products.
It was found that the external surfactant used to solidify the
nanosuspension (nanoMel) increased the degree of crystal-
linity and decreased the dissolution rate of Mel. This change
is related to the solubility-enhancing effect of the surfactant.
It was concluded that, in the absence of surfactant, the critical
product parameters can be fulﬁlled by optimization of process
parameters of ﬂuidization and lyophilization.
Fluidization (ﬂuidMel)
MCC as the carrier material was used in a Strea-1 (Niro
Aeromatic, Bubendorf, Switzerland) ﬂuid-bed chamber.
A batch size of 100.0 g was used. The powder was inserted
and ﬂuidized in the preheated chamber for a period of
10 min and at a constant air velocity of 2.5 m/s.
NanoMel as liquid dispersion was transported by
a peristaltic pump (Roto Consulta, Ebikon/Luzern,
Schweiz), the applied pump speed was 9 rpm. One batch
of 200.0 g of nanoMel dispersion was atomized onto the
surface of the material. The process took 50 mins, the inlet
temperature was 55°C and the outlet temperature was 38°
C. The ﬁnal concentration of the components in percen-
tage is shown in Table 1. The yield of the process was
Table 1 Composition of the Investigated Samples
Sample Mel
(%)
PVA
(%)
Water
(%)
MCC
(%)
Trehalose
(%)
nanoMel 1.00 0.50 98.50 – –
ﬂuidMela 1.94 0.97 – 97.09 –
lyoMelb 15.38 7.70 – – 76.92
Notes: a,bBased on dry material.
Abbreviations: Mel, meloxicam; PVA, poly(vinyl alcohol); MCC, microcrystalline
cellulose.
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calculated based on the proportion of the mass of the
components before and after the operation.
Lyophilization (lyoMel)
Freeze-drying was performed in Scanvac CoolSafe 100–9
Pro type equipment (LaboGene ApS, Lynge, Denmark)
equipped with a 3-shelf sample holder unit, recessed into
the drying chamber. In each cuvette 750 mg of diluted
milled suspension was ﬁlled (7.5 mg Mel content in every
cuvette, the unit dose of Mel). As a cake-forming additive,
37.5 mg of (5.0%) trehalose was dissolved in the nanosus-
pensions. The components of the ﬁnal product can be seen
in Table 1. The process was controlled by a computer
program (Scanlaf CTS16a02), the temperature and pres-
sure values were recorded continuously. The whole pro-
cess took 71 hrs and 52 mins. The initial temperature was
25°C. During the freezing period, after 18 hrs and 34 mins,
the sample temperature was decreased to −40°C. The sub-
sequent drying process was conducted at 0.013 mbar air
pressure for 50 hrs and 50 mins, the temperature increased
from −40°C to −7°C. Finally, the secondary drying session
took 2 hrs and 28 mins. The ﬁnal temperature of the dried
products was 30°C.
Characterization of Nanosuspension and the
Solid-State Forms
Particle Size Measurements
The investigations on the particle size of rawMel el and
nanoMel via laser diffraction were executed (Malvern
Mastersizer S 2000, Malvern Instruments Ltd,
Worcestershire, UK) with the following parameters: 300RF
lens; small volume dispersion unit (1,000 rpm); refractive
index for Mel: 1.596; and refractive index for dispersion
medium: 1.330. During the measurements, distilled water
was used as a dispersant, and obscuration was in the range
of 11–16% for all measurements. In both cases, the particle
size distributions were qualiﬁed by d(0.1), d(0.5), and d(0.9) (d
(0.5) is the particle diameter below which 50% of the sample
volume exists).
In the case of the solid-state products (ﬂuidMel and
lyoMel), the particle size of Mel was determined by using
Scanning Electron Microscopy (SEM) images (Hitachi
S4700, Hitachi Scientiﬁc Ltd., Tokyo, Japan). The size of
the particles was calculated by ImageJ software for
Windows (Phase GmbH, Lübeck, Germany).37 By speci-
fying the unit length, which is shown in each image
(depending on the magniﬁcation this is a different value),
the actual particle size can easily be determined by
drawing the diameter of the captured particles.
A diameter of a hundred captured particles was determined
in the case of two solid-state samples.
For nanoMel and lyoMel samples, the Z-average par-
ticle size and the polydispersity index (PDI) of Mel were
measured using a Malvern Zeta Nano ZS (Malvern
Instruments Ltd). In case of the particle size determination,
Malvern DTS 1070 folded capillary cell was used. The
samples were further diluted with water (25-fold) for the
measurements.
Morphology of the Samples (SEM)
For SEM investigations, nanoMel samples were dried in
a vacuum dryer (Binder GmbH, Tuttlingen, Germany) at
40°C in order to obtain solid products, and ﬂuidMel and
lyoMel were visualized as well. The samples were sputter-
coated with gold–palladium under an argon atmosphere,
using a gold sputter module in a high-vacuum evaporator,
and the samples were examined at 10 kV and 10 mA. The
air pressure was 1.3–13 MPa.
Differential Scanning Calorimetry (DSC)
To investigate the occurring physico-chemical changes and to
predict the crystallinity of the solid-state products, DSC mea-
surements were carried out with a Mettler Toledo DSC 821e
thermal analysis system with the STARe thermal analysis
software V9.0 (Mettler Inc. Schwerzenbach, Switzerland).
Approximately 2–5 mg of the physical mixtures (PM) and
the product samples were examined in the temperature range
of 25–300°C. The heating rate was 20°C/min in the presence
of argon as a carrier gas with a ﬂow rate of 10 L/h. The
calculations of Mel crystallinity (Cryst %) were performed
using the area under the curve (AUC) of the melting enthalpy
of the products (AUCMel) and the physical mixtures
(AUCMelPM).38 The values were compared using the follow-
ing formula:
Cryst% ¼ AUCMel
AUCMelPM
 100
Stability Test
The products (ﬂuidMel and lyoMel) were stored in a well-
closed container, at room temperature (23 ± 2°C, 45 ± 5%
RH) for 6 months. The crystallinity of Mel was investi-
gated compared to freshly measured products.
Drug Content Determination
The Mel content of the samples was controlled in the
following way. The unit dose of the products with
Bartos et al Dovepress
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0.75 mg of theoretical Mel was dissolved in 100 mL of
phosphate buffer pH 7.4 ± 0.1. The sample was stirred with
a magnetic stirrer at 25°C for 24 hrs and then ﬁltered (0.1
μm, FilterBio PES Syringe Filter) (Labex Ltd., Budapest,
Hungary), and the concentration of the dissolved Mel was
analyzed spectrophotometrically (Unicam UV/VIS)
(Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA) at
364 nm wavelength. The investigations were repeated
three times.
Solubility Testing of MEL in the Samples
The solubility of Mel in the samples (nanoMel, ﬂuidMel
and lyoMel) was determined. The dispersions were stirred
with a magnetic stirrer at 25°C for 24 hrs and then ﬁltered
(0.1 μm, FilterBio PES Syringe Filter) (Labex Ltd.,
Budapest, Hungary), and the dissolved drug content was
analyzed spectrophotometrically (Unicam UV/VIS)
(Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA) at
364 nm wavelength (n = 3).
In vitro Dissolution Test
To determine the dissolution extent of Mel from different
products, the paddle method (USP dissolution apparatus,
type II Pharma Test, Hainburg, Germany) was used. The
medium was 900 mL of artiﬁcial gastric ﬂuid at pH 1.2 ±
0.1. The paddle was rotated at 100 rpm and sampling was
performed up to 120 min. The Mel content of the samples was
determined with a spectrophotometer (ATI-UNICAM UV/
VIS Spectrophotometer, Cambridge, UK) at 362 nm. The
number of parallels was three.
Statistical Analyses
Data from the above methods were expressed as means
±SD, and groups were compared by using Student’s t-test.
Differences were considered statistically signiﬁcant when
p<0.05.
In vivo Studies
All experiments involving animal subjects were carried out
with the approval of the National Scientiﬁc Ethical Committee
on Animal Experimentation (permission number: IV/1247/
2017). The animals were treated in accordance with the
European Communities Council Directives (2010/63/EU)
and the Hungarian Act for the Protection of Animals in
Research (Article 32 of Act XXVIII). Each sample contained
60 µg/mL of Mel and 30 µg/mL of PVA in distilled water. For
per os delivery, the different formulations were individually
diluted and were given at a single dose of 300 μg/kg of Mel to
male Sprague–Dawley rats (8 weeks old, 240–260 g, n = 6) in
a volume of 0.5 mL by gastric gavages. All animals fasted 16
hrs before the per os administration of drugs. In order to
facilitate the absorption, the solid-state forms were re-
dispersed in water immediately before administration. In
a comparison study for intravenous administration, animals
were treated with a 300 µg/kg bolus of Mel via the tail vein.
Intravenous (IV) injection was prepared by the dilution
of passable injection with a concentration of 15 mg/1.5 mL
(Meloxicam-Zentiva, Prague, Czech Republic) to reach the
ﬁnal concentration (0.15 mg/mL). The ingredients of the
injection were meglumine, poloxamer 188, glycine,
sodium hydroxide (for pH adjustment), sodium chloride,
glycopherol, and water for injection. Blood samples were
collected from the tail vein before and at 15, 30, 60, 75,
90, 120 and 180-mins post-dosing. Plasma samples were
collected into EDTA containing polyethylene tubes, cen-
trifuged at 1,500 g for 10 min at 5°C. Separated plasma
samples were stored at −80°C until extraction and
analysis.
Determination of Mel from Rat Plasma
Preparation of plasma samples, calibration standards and
quality control samples
To 90 µL of plasma sample, 10 µL of 0.1% aqueous
formic acid and 300 µL of acetonitrile containing piroxicam
(internal standard at 12.5 ng/mL concentration) were added
and the mixture was vortex-mixed for 60 s. The mixture was
allowed to rest for 30 mins at −20°C to support protein
precipitation. The supernatant was obtained by the centrifu-
gation of the mixture for 10 min at 10,000 g at 4°C and 20 µL
was diluted with 380 µL of 0.1% aqueous formic acid.
Finally, 5 µL was injected into the LC–MS/MS system for
analysis.
Rat plasma calibration standards of meloxicam were
prepared by spiking the working standard solutions (1–1000
ng/mL) into a pool of drug-free rat plasma and the proce-
dure described above was followed. Calibration standards
consisted of 90 µL of pooled drug-free plasma, 10 µL of
meloxicam standard solution (in 0.1% aqueous formic acid)
and 300 µL of acetonitrile containing piroxicam (internal
standard at 12.5 ng/mL concentration). Solutions contain-
ing 6.25 ng/mL and 25 ng/mL of meloxicam were used as
QC samples. 20 µL of supernatant was taken out from both
of the calibration standards and the QC samples, diluted
with 380 µL of 0.1% aqueous formic acid, and 5 µL was
analyzed by LC–MS/MS.
Dovepress Bartos et al
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LC–MS/MS Analysis of Meloxicam
The quantitative analysis of meloxicam was performed by
mass spectrometry after the chromatographic separation of
analytes. An Agilent Liquid Chromatography System series
1100 (Micro Vacuum Degasser, Capillary Pump, µ-WPS
autosampler) (Agilent Technologies, Waldbronn, Germany)
was connected to a Q ExactiveTM Plus Orbitrap mass
spectrometer (Thermo Fisher Scientiﬁc, San Jose, US)
equipped with a heated ESI ion source. Gradient chromato-
graphic separation was performed at room temperature on
a LunaR 5 µm C8(2) Mercury column (20 mm x 2.0 mm)
protected by a C8 guard column (2x2 mm) (Phenomenex,
Torrance, USA) using ammonium formate (15 mM, pH = 3)
as Solvent A and acetonitrile as Solvent B (Table 2). The
calibration curve was shown to be linear over the concentra-
tion range of 1–1000 ng/mL
The mass spectrometer was used in positive mode with
the following parameters of H-ESI source: ion spray vol-
tage at 3.5 kV, capillary temperature at 253°C and aux gas
heater temperature at 406°C, sheath gas ﬂow rate at 46 l/h,
aux gas ﬂow rate at 11 l/h, sweep gas ﬂow rate at 2 l/h and
S-lens RF level at 50.0 (source auto-defaults). Multiple-
reaction-monitoring (MRM) mode was used for quantiﬁ-
cation by monitoring the transitions: m/z 352→115 and
352→141 for meloxicam (collision energy 24 V) and m/z
332→95 and 332→121 for piroxicam (collision energy 29
V). A divert valve placed after the analytical column was
programmed to switch ﬂow onto MS only when analytes
of interest elute from the column (plasma samples: 0.7–2.0
mins) to prevent the excessive contamination of the ion
source and ion optics.
Data acquisition and processing were carried out using
Xcalibur and Quan Browser (version 4.0.27.19) software
(Thermo Fisher Scientiﬁc, San Jose, US).
The area under the curve (AUC) of the time (min)–
concentration (ng/mL) curves of each animal and the sta-
tistical analysis were performed with Prism 5.0 software
(GraphPad Software Inc., La Jolla, CA, USA). All data
presented are means ± SD. The unpaired t-test was used to
determine statistical signiﬁcance. Changes were consid-
ered statistically signiﬁcant at p < 0.05. The ratio of
AUC value, after the per oral application of the trans-
formed samples (AUCﬂuidMel, AUClyoMel) in compar-
ison with the AUC of the peroral application of nanoMel
(AUCnanoMel) as relative bioavailability (rel.BA) was
determined according to the formula below:39
rel:BA for plasma %ð Þ ¼ AUCtransformed sample
AUCnanoMel
 100
In vitro–in vivo Correlation Calculation
In vitro–in vivo correlation (IVIVC) is a biopharmaceutical
tool for the investigation of the mutual relationship of the
dissolution characteristics of the in vitro and in vivo absorp-
tion studies.40 In our case, the Pearson’s correlation coefﬁ-
cient of the AUC values of the in vitro and in vivo results was
calculated by Microsoft Excel (Microsoft Corporation,
Redmond, Washington, US) and Statistica for Windows
(StatSoft GmbH, Hamburg, Germany). The three prepared
samples were correlated with each other in groups of in vitro
and in vivo. To determine statistical signiﬁcance, the
unpaired t-test was used.
Results and Discussion
Particle Size Measurements
Different techniques have been used to determine the parti-
cle size of Mel for reasons of accuracy and comparability.
The particle size distribution of the rawMel and nanoMel
samples was investigated via laser diffraction. A combined
wet milling process resulted in a 200-fold particle size
reduction in the case of nanoMel (d(0.50), 130±5 nm)
compared to the raw drug particle size (d(0.50), 34.26
±4.86 µm). The nanoMel product showed a monodisperse
distribution (d(0.10), 67±1nm; d(0.50), 130 ± 5 nm; d(0.90),
371±12 nm).
For ﬂuidMel sample, Mel particles adhered to the
carrier surface (MCC) was analyzed by the ImageJ tech-
nique and the particle size of Mel in the nanoMel and
lyoMel samples were compared with dynamic light scat-
tering technique (Malvern nanoZS), too. The results
demonstrate that the d(0.50) value of the Mel nanoparti-
cles measured on the surface of solid phase product
Table 2 The Gradient Elution Program Applied for Analysis
t (min) B (%) Flow Rate (µL/min)
0 40 250
0.5 40 250
2 70 250
2.1 90 600
2.5 90 600
2.6 40 600
4.0 40 600
4.1 40 250
4.5 40 250
Abbreviation: B, solvent (acetonitrile).
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(ﬂuidMel) does not show a signiﬁcant difference regarding
the d(0.50) value of the nanoMel (Figure 1A). In the case
of lyoMel, compared to the Z-average of Mel in nanoMel,
a signiﬁcant difference can already be detected which was
caused by the recrystallization of the Mel (Figure 1B).
Both samples have the same polydispersity index
(nanoMel: 0.273 and lyoMel: 0.287) which also conﬁrms
the monodispersity of nanoMel and shows the excellent
redispersibility of lyoMel. The 6-month storage did not
cause any further changes in the mean particle size of the
products (Figure 1A and B).
SEM Measurements
Figure 2A and B clearly show the particle size difference
between the rawMel and nanoMel and the change in the
particle habit. The latter particles have smooth surfaces
with rounded edges and corners. High mechanical impact
results in the fracture and abrasion of the crystals.
During the ﬂuidization process, the nanoparticles are
uniformly adhered to the surface of MCC (Figure 2C1).
Their habit is the same as that of the nanoparticles in the
nanoMel (Figure 2C2). There is no sign indicating the
aggregation of the nanoparticles on the surface of MCC.
The adhesion of the Mel particles to the carrier surface is
also supported by the effect of the PVA adhesive property
and the rapid evaporation of water.
The SEM image of the lyoMel sample (Figure 2D1)
shows large, consistent formulas at low magniﬁcation. The
texture at higher magniﬁcation contains smaller, larger
pores resulting in a big surface with honeycombed struc-
ture, where the surface area is determined by the size of
the ice crystals.41 The SEM picture does not show any
trehalose-like crystals in the structure (Figure 2D2).
DSC Measurements, Crystallinity
Determination
The DSC curves of the components and the products are
shown in Figure 3. The rawMel has a relatively high
melting point at 268°C, PVA as semi-crystalline material
has two endothermic peak at 169°C and at 222°C. MCC
shows any characteristic peak; in contrast, the trehalose is
a crystalline material (Figure 3A).
The thermograms of the products are shown in Figure 3B.
It is clear that the melting point and the enthalpy ofMel in the
case of the nanoMel decreased due to the partial
amorphization.
The curve of the ﬂuidMel shows the peak of MCC and the
decreased melting point of Mel (Figure 3B). The ﬁrst obvious
and big endothermic peak of the curve appearing from 30°C to
150°C is mainly related to the absorbed moisture
evaporation.42 The second endothermic peak is connected to
the melting point of Mel (264°C) and the enthalpy was
decreased due to the large amount of MCC, which covered
the characteristic peak of PVA as well, compared to nanoMel.
The curve of lyoMel represents the peak of PVA (197°C)
and the melting temperature of Mel (251°C) (Figure 3B).
According to the literature43 and our measurements, during
the process, the total amount of trehalose transformed into an
amorphous form and the lyophilized trehalose maintains its
amorphous form. The big endothermic peak of the curve
appearing from 30°C to 150°C is connected to the absorbed
water evaporation as well.
The crystallinity of Mel in nanoMel and the trans-
formed solid-state products were calculated by the
enthalpy changes of the drug occurring during the DSC
measurement (Table 3). Each sample was compared to its
own physical mixture. According to the crystallinity of the
nanoMel (13.43%) sample, the crystallinity of the ﬂuidMel
sample did not change (12.98%), for the lyoMel sample
partial recrystallization (40.11%) occurred.
After 6 months of storage (23 ± 2°C, 45 ± 5% RH), the
degree of crystallinity of solidiﬁed samples (ﬂuidMel and
lyoMel) was determined again. The results did not show
a signiﬁcant change (p>0.05) compared to the non-stored,
fresh samples (Table 3). There was no sign for the recrys-
tallization of trehalose.
Drug Content Determination
The theoretical drug content was 7.50 mg as a single dose/
oral. For the nanoMel sample, this amount was 7.12 mg
and ﬂuidMel showed 6.83 mg of Mel. The latter can be
related to the yield of the ﬂuidization technique (95.93%).
During the lyophilization process, the Mel content of the
sample (lyoMel) was 7.12 mg.
Solubility Testing of MEL in the Samples
The solubility of nanoMel increased signiﬁcantly (9.4 ± 0.5
µg/mL) in comparison with the rawMel (6.5±0.2 µg/mL). The
reduced particle size enhanced the wettability of the hydro-
phobic particle when using PVA, therefore increased the ther-
modynamic solubility of Mel. The ﬂuidization process did not
affect the solubility of Mel (9.6 ± 0.4 µg/mL). In the case of
lyoMel, solubility was increased (11.2 ± 0.5 µg/mL) because
of the presence of trehalose.
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Figure 1 (From left to the right). Main particle size of nanoMel (measured by laser diffraction), ﬂuidMel fresh and ﬂuidMel stored (6 months) (measured by SEM images) (A)
and Z-average of nanoMel, lyoMel fresh, and lyoMel stored (6 months) (measured by Zeta nano ZS) (B).
Abbreviations: Mel, meloxicam; SEM, scanning electron microscopy.
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In vitro Dissolution Studies
The in vitro dissolution extent of the samples was inves-
tigated in gastric juice (pH=1.2). Mel has a week acidic
character; therefore, its solubility in this medium is very
poor (1.6 ± 0.2 µg/mL, at 37°C). Figure 4 clearly demon-
strates that the particle size reduction of Mel in the nano-
suspension (nanoMel) inﬂuenced the dissolution rate of
Mel but resulted in only 40% of drug release in 5 mins,
and then the curve took a stagnant proﬁle. The initial rapid
drug release can be associated with the nanoscale Mel and
its amorphous structure. The 2-hrs test did not result in any
more favorable results. Although the distribution of the
nanoparticles of Mel in the nanosuspension is suitable,
a large volume of acidic medium (900 mL) may increase
the aggregation of the nanoparticles. In this case, the
protective effect of the polymer (PVA) is unsatisfactory.
For ﬂuidMel and lyoMel samples, a rapid initial phase
is observed (about 60% of the drug is dissolved in 15
Figure 2 SEM image of rawMel (A), nanoMel (B), ﬂuidMel (C1 and C2) and lyoMel (D1 and D2).
Abbreviations: Mel, meloxicam; SEM, scanning electron microscopy.
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Figure 3 DSC curves of rawMel (black), PVA (red), MCC (blue) and trehalose (purple) (A), and nanoMel (orange) ﬂuidMel (green) and lyoMel (yellow) (B).
Abbreviations: DSC, differential scanning calorimetry; Mel, meloxicam; PVA, poly(vinyl alcohol).
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mins), followed by a slowing but rising proﬁle. About
75% of Mel was dissolved within 2 hrs. In the case of
the solid-state forms, carriers (MCC and trehalose) help to
uniformly distribute the nanoparticles of Mel, thereby
maintaining the uniqueness of the nanoparticles.
In vivo Studies
The plasma concentration of the samples in rats is shown in
Figure 5. The calculated plasma concentration of Mel at 0 min
(C0min) was 10,607 nM, and then the plasma concentration
decreased exponentially. A very small amount of Mel was
absorbed from the nanoMel sample, regardless of the particle
size of the drug. The plasma concentration of Mel was con-
stant in the investigated time period. The results show that the
nanosuspension (nanoMel) has not got advantageous
properties.
The initial blood levels of the ﬂuidMel and lyoMel
samples show a big difference. At 15 mins, the lyoMel
sample (5,712.98 nM) shows more than twice the value of
ﬂuidMel (Table 4). In practice, this value is similar to the
maximum plasma level for the lyophilized product (C30min
5,814 nM). The peak blood concentration of ﬂuidMel is
about 6,000.00 nM at 50 mins that is comparable with the
blood concentration reached by IV injection at 5 mins.
This result also conﬁrms that the solid products contained
Mel in an adequate amount and that the total amount
thereof dissolved and absorbed.
The plasma curves of the different samples containing
Mel show a very slow elimination after the distribution
phases. That can be explained by the very high (99%)
plasma binding property of Mel in rat, and this ratio is
the same in human.44 It seems that the eliminated portion
of Mel is replenished from the protein bounded fraction
for a quite long period of time. Our measuring time was
only 3 hrs, longer detection period can provide appropriate
information about the whole elimination process. The peak
MEL concentrations of from lyoMel and ﬂuidMel prepara-
tions have reached a similar level that of IV formula
(Figure 5). The lyoMel sample resulted in higher plasma
concentrations in 15 mins as compared with nanoMEL
preparation. The solidiﬁed samples had nearly ﬁve-fold
higher bioavailability than that of nanoMel (Table 4).
IVIV Correlation
Comparative studies according to AUC values have shown
that there are signiﬁcant differences between the nanosus-
pension and the samples (ﬂuidMel and lyoMel) within
in vitro and in vivo groups. However, there is no signiﬁ-
cant difference between two solid samples either in vitro
or in vivo (Figure 6). The basis of the IVIVC calculation
was the comparison of the AUC values of the samples in
the in vitro and in vivo groups. By our calculations, the
Table 3 Enthalpy and Calculated Crystallinity Values of the
Characteristic Peak of Mel in the Samples
Sample Enthalpy
(J/g)
Crystallinity
of Mel (%)
Crystallinity of Mel
After 6 Months of
Storage (%)
nanoMel 12.24 13.43 –
ﬂuidMel 11.83 12.98 13.02
lyoMel 36.54 40.11 40.16
Abbreviation: Mel, meloxicam.
Figure 4 In vitro dissolution of Mel from investigated samples. Medium: artiﬁcial
gastric juice (pH: 1.2).
Abbreviation: Mel, meloxicam.
Figure 5 Plasma levels of MEL after the administration of different samples in rats.
The preparations were administered orally (nanoMel, ﬂuidMel and lyoMel) or
intravenously (IV) as a single dose of 300 μg/kg.
Abbreviation: Mel, meloxicam.
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Pearson’s correlation coefﬁcient value between the two
studies is 0.99695. The t value of the independent t-test
of the two dissolution study series was 0.0145, the calcu-
lated p value was 0.9889 and the difference is not signiﬁ-
cant at a conﬁdence level of 95%. As the zero hypothesis
of the independent t-test, the calculation is not signiﬁcant
if the averages of the two series are equal. It can be
concluded that in this system, in vitro dissolution studies
are applicable to predict the dissolution rate-limited differ-
ences in the case of in vivo studies.
Conclusion
Mel-containing surfactant-free nanosuspension (nanoMel)
as an intermediate product was produced by the wet
milling process (planetary ball mill was combined with
pearl milling technology). The energy invested in the
milling decreased the mean particle size of Mel (130 nm)
and broke the crystal structure of the nanoparticles (crys-
tallinity index: 13.43%). This can be considered a labile
system, so stabilizing a suspension as a ﬁnal dosage form
without a surfactant does not work; therefore, the solidiﬁ-
cation of the nanoMel produced by ﬂuidization and
lyophilization was chosen to ensure the critical product
parameters (particle size, degree of crystallinity). We stu-
died also the inﬂuence of solidiﬁcation of nanoMel on the
physical stability and drug bioavailability of the products.
The nanoMel product had an optimized amount of PVA
(0.5%) as a protective polymer, but no surfactant as
a further stabilizing agent because the ﬁnal aim was to
produce surfactant-free solid phase products as well.
The solidiﬁcation studies showed that the critical pro-
duct parameters of the intermediate product (nanoMel)
were primarily provided by the ﬂuidization technique
which resulted in no signiﬁcant change in mean particle
size and crystallinity degree of Mel compared to the
nanoMel. It is connected to the short operation time (50
mins), the large surface area of the MCC which ﬁxed the
nanoparticles with the sticking effect of the PVA and the
crystallization inhibitory property of the ﬁbers.33 The lyo-
philization required a longer operation time (72 hrs),
which resulted in the amorphization of the crystalline
carrier (trehalose)45 and the recrystallization of Mel with
an increased particle size and crystallinity degree. Finally,
it was found that the physical stability of the solid phase
products (ﬂuidMel, lyoMel) was no change in particle size
and crystallinity at 6 months of storage at room tempera-
ture (23 ± 2°C, 45 ± 5% RH) compared to freshly mea-
sured products.
In our previous work (DDDT, 2018),10 there was per-
formed a human Caco-2 intestinal epithelial cell line via-
bility assay. Impedance measurement did not show
signiﬁcant cell damage after treatments with Mel, PVA-
Mel formulations, as reﬂected by unchanged cell index
values. The epithelial electrical resistance studies pre-
dicted the rapid penetration of nanonized Mel. In vivo
studies justiﬁed the predicted data. The nanonized Mel in
solidiﬁed products (ﬂuidMel, lyoMel) resulted in rapid
absorption through the gastric membrane by passive trans-
cellular transport. It was found that the solid products
contained Mel in an adequate amount and that the total
amount thereof dissolved and absorbed. It has to be noted
Table 4 Plasma Concentrations of Mel in Time and Its Relative Bioavailability in Rats After IV and per Os Administration of Mel
Samples. Relative Bioavailabilities Were Compared to nanoMel Preparation
Sample C15min (nM) C120min (nM) AUCblood (min·ng/mL) Relative Bioavailability (%)
nanoMel 1,090.02±13.11 1,123.31±14.24 190,584.52 100.00
ﬂuidMel 2,338.44±17.25 5,811.33±18.34 945,834.99 496.28
lyoMel 5,712.98±28.36 5,219.52±20.86 923,117.95 484.36
IV injection C5min 6,059.07±15.76 2,607.80±19.52 377,528.01 –
Abbreviations: Mel, meloxicam; C15min, C120min, plasma concentrations of Mel in time; AUCblood, area under the time–concentration curve AUC interval is t0min-t180 min.
Figure 6 IVIV correlation of Mel-containing samples.
Notes: Values are presented as mean ± SD. Statistically signiﬁcant differences are:
***p<0.001, compared to nanoMel separately in in vitro and in vivo groups; #
p<0.05 compared to the indicated columns.
Abbreviations: Mel, meloxicam; AUC, area under the time–concentration curve;
IVIV correlation, in vitro-in vivo correlation; SD, standard deviation.
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that Mel shows a very slow elimination because of very
high plasma binding (99%) in rat, and its replenishing time
is quite a long period. MEL blood concentrations of
lyoMel and ﬂuidMel were similar to the level of IV form.
The solidiﬁed samples had nearly ﬁve-fold higher rela-
tive bioavailability than nanoMel application by oral
administration and IVIV correlation was found between
the in vitro and in vivo studies. The correlation between
in vitro and in vivo studies showed that Mel nanoparticles
ﬁxed on the solid carrier (MCC, trehalose) in both the
artiﬁcial gastric juice and the stomach of the animals
rapidly reach saturation concentration leading to rapid
absorption. These products show about 5 times greater
bioavailability than the nanosuspension, in which the Mel
nanoparticles can be aggregated in the stomach.
It can be stated that in the present study, the solidiﬁca-
tion of the nanosuspension (nanoMel) not only increased
the stability of the nanoparticles but also allowed the
preparation of surfactant-free solid compositions (powder,
tablet, capsule), which may be an important consideration
for certain groups of patients to achieve rapid analgesia.
Further experiments are necessary to prove the therapeutic
relevance of these innovative formulations.
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